Background. Massive research capacities are aiming to establish certain associations between various gene-candidates and prognosis in cardiovascular disease. Underlying hyperactivation of aldosterone synthase resulting in sodium and volume retention, as well as potent properties that modify oxidative stress, connective tissue proliferation with further cardiovascular remodeling are mechanisms that reflect the key role of aldosterone synthesis genes in onset and progression of hypertension.

Aim of the review. Current article aimed to evaluate perspectives and opportunities of early target organ damage prognosis and antihypertensive treatment administration in hypertensive patients with variable CYP11B2 gene allelic variants.

Results. Review contains the most recent data about potential role of aldosterone-synthase gene polymorphism in development of target organ damage in hypertensive individuals. Studies in different populations accumulate growing, but still conflicting evidence of various allelic variants of CYP11B2 significant influence on hypertension onset and such endpoints as left ventricle myocardial remodeling, hypertensive chronic kidney disease, cognitive impairment, and stroke. Studies in different ethnic groups and population represent controversial data about possible association of genotype and antihypertensive treatment response. There is lack of aldosterone synthase gene polymorphism studies in population of hypertensive patients inUkraine.

Conclusions. Thus, further prospective studies, evaluating risk of excessive mineralocorticoid activation and personalized pharmacogenetic profile in hypertensives are required. Practical implication of various genotyping methods, including express techniques can possibly improve outcomes for hypertensive patients.